GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Estrella Immunopharma Inc (NAS:ESLA) » Definitions » Cash Ratio

ESLA (Estrella Immunopharma) Cash Ratio : 23.01 (As of Jun. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Estrella Immunopharma Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Estrella Immunopharma's Cash Ratio for the quarter that ended in Jun. 2024 was 23.01.

Estrella Immunopharma has a Cash Ratio of 23.01. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.

The historical rank and industry rank for Estrella Immunopharma's Cash Ratio or its related term are showing as below:

ESLA' s Cash Ratio Range Over the Past 10 Years
Min: 0.25   Med: 4.32   Max: 23.01
Current: 23.01

During the past 4 years, Estrella Immunopharma's highest Cash Ratio was 23.01. The lowest was 0.25. And the median was 4.32.

ESLA's Cash Ratio is ranked better than
94.51% of 1475 companies
in the Biotechnology industry
Industry Median: 2.82 vs ESLA: 23.01

Estrella Immunopharma Cash Ratio Historical Data

The historical data trend for Estrella Immunopharma's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Estrella Immunopharma Cash Ratio Chart

Estrella Immunopharma Annual Data
Trend Jun21 Jun22 Jun23 Jun24
Cash Ratio
- 4.32 0.25 23.01

Estrella Immunopharma Quarterly Data
Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.25 1.28 22.67 34.25 23.01

Competitive Comparison of Estrella Immunopharma's Cash Ratio

For the Biotechnology subindustry, Estrella Immunopharma's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Estrella Immunopharma's Cash Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Estrella Immunopharma's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Estrella Immunopharma's Cash Ratio falls into.



Estrella Immunopharma Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Estrella Immunopharma's Cash Ratio for the fiscal year that ended in Jun. 2024 is calculated as:

Cash Ratio (A: Jun. 2024 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=4.165/0.181
=23.01

Estrella Immunopharma's Cash Ratio for the quarter that ended in Jun. 2024 is calculated as:

Cash Ratio (Q: Jun. 2024 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=4.165/0.181
=23.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Estrella Immunopharma  (NAS:ESLA) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


Estrella Immunopharma Cash Ratio Related Terms

Thank you for viewing the detailed overview of Estrella Immunopharma's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Estrella Immunopharma Business Description

Traded in Other Exchanges
N/A
Address
5858 Horton Street, Suite 170, Emeryville, CA, USA, 94608
Estrella Immunopharma Inc is a preclinical-stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors. Estrella's mission is to harness the evolutionary power of the human immune system to transform the lives of patients fighting cancer.

Estrella Immunopharma Headlines